Bellerophon Therapeutics logo

Bellerophon TherapeuticsNASDAQ: BLPH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 February 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$464.84 K
-99%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 14:30:00 GMT
$0.04+$0.00(+2.70%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

BLPH Latest News

Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?
InvestorPlace25 July 2023 Sentiment: NEGATIVE

Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of BLPH stock come Friday unless it requests a meeting with the Nasdaq Hearings Panel.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
Benzinga05 July 2023 Sentiment: POSITIVE

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Zacks Investment Research06 June 2023 Sentiment: NEGATIVE

Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?
Zacks Investment Research06 June 2023 Sentiment: POSITIVE

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Market Watch05 June 2023 Sentiment: NEGATIVE

Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated “minimal difference” between studied groups, with none approaching statistical significance.

Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?
InvestorPlace05 June 2023 Sentiment: NEGATIVE

Bellerophon Therapeutics (NASDAQ: BLPH ) stock is taking a massive beating on Monday after the pharmaceutical company posted poor clinical trial results. The bad news for BLPH stock comes from its Phase 3 clinical trial of INOpulse as a treatment for fibrotic Interstitial Lung Disease (fILD).

5 Stocks With Recent Price Strength Amid March Rally
Zacks Investment Research03 April 2023 Sentiment: POSITIVE

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH.

Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research28 March 2023 Sentiment: POSITIVE

Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

What type of business is Bellerophon Therapeutics?

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

What sector is Bellerophon Therapeutics in?

Bellerophon Therapeutics is in the Healthcare sector

What industry is Bellerophon Therapeutics in?

Bellerophon Therapeutics is in the Biotechnology industry

What country is Bellerophon Therapeutics from?

Bellerophon Therapeutics is headquartered in United States

When did Bellerophon Therapeutics go public?

Bellerophon Therapeutics initial public offering (IPO) was on 13 February 2015

What is Bellerophon Therapeutics website?

https://bellerophon.com

Is Bellerophon Therapeutics in the S&P 500?

No, Bellerophon Therapeutics is not included in the S&P 500 index

Is Bellerophon Therapeutics in the NASDAQ 100?

No, Bellerophon Therapeutics is not included in the NASDAQ 100 index

Is Bellerophon Therapeutics in the Dow Jones?

No, Bellerophon Therapeutics is not included in the Dow Jones index

When was Bellerophon Therapeutics the previous earnings report?

No data

When does Bellerophon Therapeutics earnings report?

Next earnings report date is not announced yet